Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Company expects to file New Drug Application

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The Company is currently proceeding with detailed analyses of the data and preparing for a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) in the upcoming months, which would be followed by the filing of a NDA for the registration of AEZS-130 in the United States.

"We wish to thank all those involved in this project for their utmost dedication. Preliminary results are encouraging and we therefore expect to submit a NDA to the FDA. We believe that AEZS-130 could become the first approved oral test for the diagnosis of AGHD, providing patients with a potentially safer, accurate and more convenient alternative to the current injectable tests", stated Juergen Engel, Ph.D., President and CEO at Aeterna Zentaris.

SOURCE AETERNA ZENTARIS INC.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Tracking BA.2.12.1 🦠 by partial ORF1ab gene 🧬 target failure (pOGTF)